Literature DB >> 7372784

Prevalence of subclinical thyroid failure in insulin-dependent diabetes.

R S Gray, D Q Borsey, J Seth, R Herd, N S Brown, B F Clarke.   

Abstract

A study was made of the distribution of primary thyroid failure, indicated by a raised serum TSH concentration, in 605 (294 males and 311 females) insulin-dependent (type I) diabetics, aged 21-84 yr, not previously suspected of having thyroid disease. The prevalence of a raised serum TSH concentration in females of all ages (17%) was significantly greater (P less than 0.0005) than that in males (6.1%) and increased with increasing age at onset of diabetes (P less than 0.05) and age at time of study (P less than 0.001) in females but not in males. There was no significant difference in the duration of diabetes when comparing patients with normal and raised serum TSH concentrations. The prevalence of a raised TSH concentration in late-onset insulin-dependent diabetics was no greater in patients requiring insulin within 3 months of diagnosis of diabetes than in those exhibiting secondary sulfonylurea failure, who required insulin more than 3 months after diagnosis. In type I diabetes, the prevalence of subclinical primary thyroid failure is considerably greater than has previously been suspected, with female late-onset insulin-dependent diabetics being at the greatest risk.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7372784     DOI: 10.1210/jcem-50-6-1034

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Thyroid disease during pregnancy.

Authors:  G N Burrow
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

2.  The influence of prolonged streptozotocin diabetes on the thyroid gland function in rats.

Authors:  K V Derkach; I V Moyseyuk; A O Shpakov
Journal:  Dokl Biochem Biophys       Date:  2013-08-23       Impact factor: 0.788

3.  Effect of antithyroid autoantibodies on pancreatic islet-cell function.

Authors:  N Kitano; T Taminato; M Seno; Y Miyamoto; Y Seino; S Matsukura; H Imura
Journal:  Acta Diabetol Lat       Date:  1987 Jan-Mar

4.  Frequency of biochemical hypothyroidism in sera referred for autoantibody testing.

Authors:  H Reyes; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1994-05

5.  Low-dose T₃ replacement restores depressed cardiac T₃ levels, preserves coronary microvasculature and attenuates cardiac dysfunction in experimental diabetes mellitus.

Authors:  Nathan Y Weltman; Kaie Ojamaa; Evelyn H Schlenker; Yue-Feng Chen; Riccardo Zucchi; Alessandro Saba; Daria Colligiani; Viswanathan Rajagopalan; Christine J Pol; A Martin Gerdes
Journal:  Mol Med       Date:  2014-05-01       Impact factor: 6.354

6.  The clinical features of diabetes with coexisting autoimmune thyroid disease.

Authors:  R S Gray; R Herd; B F Clarke
Journal:  Diabetologia       Date:  1981-06       Impact factor: 10.122

7.  Anti-tubulin antibodies in recent onset type 1 (insulin-dependent) diabetes mellitus: comparison with islet cell antibodies.

Authors:  B Rousset; B Vialettes; F Bernier-Valentin; P Vague; M Beylot; R Mornex
Journal:  Diabetologia       Date:  1984-10       Impact factor: 10.122

8.  Differentiation expression during proliferative activity induced through different pathways: in situ hybridization study of thyroglobulin gene expression in thyroid epithelial cells.

Authors:  V Pohl; P P Roger; D Christophe; G Pattyn; G Vassart; J E Dumont
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

9.  Prevalence of subclinical hypothyroidism in adults visiting primary health-care setting in Riyadh.

Authors:  Eidan Al Eidan; Saeed Ur Rahman; Saeed Al Qahtani; Ali I Al Farhan; Imad Abdulmajeed
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-02-06

10.  Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes mellitus.

Authors:  Fupeng Liu; Qing Yang; Ning Gao; Fangfang Liu; Shaohua Chen
Journal:  J Diabetes Res       Date:  2014-06-04       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.